| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 435369000 | Renal origin or derivative | 23 |
| 20080299655 | Methods of tissue repair and regeneration and tissue engineered compositions - Provided are methods and compositions for constructing stable mammalian embryonic epithelial tissues and organs as well as constructing kidney tissue, and treating renal failure. Disclosed are methods of using an active epithelial growth factor having the capability of effectuating induction of growth and morphogenesis is cells. | 12-04-2008 |
| 20090029466 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA - The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery. | 01-29-2009 |
| 20100041141 | METHODS AND COMPOSITIONS RELATING TO IMPROVED LENTIVIRAL VECTORS AND THEIR APPLICATIONS - The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosaftey and promoters such as the EF1α promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs. | 02-18-2010 |
| 20100055786 | METHOD FOR TREATING KIDNEY DISORDERS - The present invention relates to a method for treating, delaying and/or preventing renal dysfunction/failure in a mammal comprising administering a therapeutically effective amount of a substance capable of inducing and/or enhancing Pax | 03-04-2010 |
| 20100261275 | Production of Recombinant Interferon Proteins - A method of purifying a recombinant interferon protein involves providing an aqueous mixture of the recombinant protein and contaminating proteins; precipitating the contaminating proteins from the aqueous mixture at a pH in a range of from 0.5 to 6; separating the aqueous mixture from the precipitated contaminating proteins; and, eluting the separated aqueous mixture through a cation exchange column using a mobile phase with a salt or pH gradient, the gradient being from lower salt concentration or pH to higher salt concentration or pH, to produce a recombinant interferon protein fraction separated from other components of the aqueous mixture. The method provides for the recovery of recombinant interferon proteins in better yield and purity. | 10-14-2010 |
| 20120034693 | RECOMBINANT VECTOR AND USE IN GENE THERAPY - A recombinant vector for delivering A3G genes into human cells comprising (i) a gene expression block including an A3G gene selected from a wild type A3G gene represented by SEQ ID NO: 1 and a mutant A3G gene and (ii) a group of elements from a modified lentiviral vector including lentiviral regions of packaging signal (ψ, psi), LTRs, RRE, and PBS; wherein said A3G gene is operably linked to the packaging signal (ψ, psi), LTRs, RRE, and PBS. | 02-09-2012 |
| 20120040457 | SMALL MOLECULES THAT REPLACE OR AGONIZE P53 FUNCTION - This invention provides a novel screening system for identifying p53 mimetics/agonists. Also provided are small organic molecules that act as effective p53 mimetics/agonists. | 02-16-2012 |
| 20120083035 | Modified Cell Lines for Increasing Lentiviral Titers - The present disclosure provides a method of modifying cells in order to enhance lentiviral titers, cell lines that are modified and modifying reagents. By mediating individual genes and combination thereof, lentiviral titers may be increased. | 04-05-2012 |
| 20120225481 | T CELL RECEPTORS - A T cell receptor (TCR) having the property of binding to the gp100 YLEPGPVTA peptide-HLA-A2 complex and comprising a TCR alpha variable domain and/or a TCR beta variable domain, characterized in that the domains are mutated relative to a TCR having the extracellular alpha and beta chain sequences SEQ ID NOs: 2 and that the TCR has a binding affinity for, and/or a binding half-life for, the YLEPGPVTA-HLA-A2 complex at least double that of a reference TCR. Embodiments of the invention such as the use of such TCRs in adoptive therapy, and fusions of such TCRs with therapeutic agents are also described. | 09-06-2012 |
| 20120301958 | BIOARTIFICIAL PROXIMAL TUBULE SYSTEMS AND METHODS OF USE - This application invention discloses bioartificial proximal tubule device, constructed by preparing a decellularized biological matrix, seeding the biological matrix with mammalian kidney-derived cells and optionally mammalian endothelial cells. The device may then be cultured statically or matured using bioreactor culture to allow differentiation of the kidney cells into functioning proximal tubule cells. The device is capable of carrying out proximal tubule functions. The application also describes various methods of making the proximal tubule devices. The application also further describes methods of use of bioartificial proximal tubule devices for e.g. in vitro studies of tubule cell transport, toxicity effects of various compounds or pharmaceutical compound screening. | 11-29-2012 |
| 20120322152 | Culture Additives To Boost Stem Cell Proliferation And Differentiation Response - The invention relates to methods of culturing and/or proliferating stem cells such as progenitor cells, multipotent and induced pluripotent stem (IPS) cells. More particularly, the invention relates to the use of macromolecular crowding created using carbohydrate-based macromolecule to promote the growth of the stem cells in an ex vivo culture, while preserving their multipotentiality. | 12-20-2012 |
| 20130143318 | COMPOSITIONS FOR INHIBITION OF RNA POLYMERASE I AND METHODS OF PRODUCTION AND USE THEREOF - Compositions for inhibition of RNA Polymerase I include peptides of Rpa43. Methods of production and use thereof are also disclosed. | 06-06-2013 |
| 20130157361 | CATALYTIC DOMAINS FROM LYSYL OXIDASE AND LOXL2 - Disclosed herein are amino acid sequences, and encoding nucleotide sequences, of isolated catalytic domains of the LOX and LOXL2 proteins from human and mouse. Methods for the preparation and use of these isolated catalytic domains are also provided. | 06-20-2013 |
| 20130183754 | NUCLEIC ACID CONSTRUCT CONTAINING A NUCLEIC ACID DERIVED FROM THE GENOME OF HEPATITIS C VIRUS (HCV) OF GENOTYPE 2a, AND A CELL HAVING SUCH NUCLEIC ACID CONSTRUCT INTRODUCED THEREIN - The present invention relates to a replicon RNA comprising a nucleotide sequence at least containing the 5′ untranslated region, the nucleotide sequence encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein, and the 3′ untranslated region on the genomic RNA of hepatitis C virus of genotype 2a. | 07-18-2013 |
| 20130183755 | THERAPEUTIC APPLICATION OF ISOLATED NATURALLY-OCCURRING SOLUBLE TRUNCATED FORMS OF IL-23 RECEPTOR - The present invention relates to an isolated naturally-occurring soluble truncated IL-23Rα protein, which is a translated protein resulting from a mRNA splice variant of IL-23Rα. The soluble IL-23Rα proteins (e.g., Δ9 and Δ8,9) represents a novel soluble IL-23Rα protein, which is lacking a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end (due to frame-shift). ELISA reveals that Δ9 is present in blood and can serve as a diagnostic tool for auto-immune diseases including Crohn's disease. There is also provided a method of recombinant production for this soluble truncated form of IL-23Rα protein. More importantly, the present invention provides an utility application of the Δ9 and Δ8,9 protein in inhibit IL-23R-mediated cell signaling. More particularly, Δ9 and Δ8,9 blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of Δ9 and Δ8,9 in treating a human patient inflicted with Crohn's disease. | 07-18-2013 |
| 20130217121 | Modified Cell Lines for Increasing Lentiviral Titers - The present disclosure provides a method of modifying cells in order to enhance lentiviral titers, cell lines that are modified and modifying reagents. By mediating individual genes and combination thereof, lentiviral titers may be increased. | 08-22-2013 |
| 20130273652 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA - The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery. | 10-17-2013 |
| 20140073049 | INDUCED PLURIPOTENT STEM CELLS PREPARED FROM HUMAN KIDNEY-DERIVED CELLS - We have disclosed an induced pluripotent stem cell and the method of preparing the induced pluripotent stem cell from a human kidney-derived cell. More particularly, we have disclosed a human kidney-derived iPS cell which may be differentiated into cells of ectoderm, mesoderm, and endoderm lineages. | 03-13-2014 |
| 20140193906 | SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY - Disclosed herein are compositions and methods for treatment of spinal muscular atrophy (SMA). In certain embodiments, compounds are provided that increase full-length survival of motor neuron (SMN) protein production by an SMN2 gene. | 07-10-2014 |
| 20160115435 | CELL CULTURE VESSEL - The present invention is to provide a cell culture vessel comprising a copolymer which contains a recurring unit containing an organic group of the following formula (a) and a recurring unit containing an organic group of the following formula (b) being coated onto a surface thereof, a method for manufacturing the same and a method for manufacturing a cell aggregate using the same (wherein U | 04-28-2016 |
| 20160138046 | COMPOSITIONS AND METHODS DIRECTED TO CRISPR/CAS GENOMIC ENGINEERING SYSTEMS - The invention relates to engineered CRISPR/Cas9 systems for genomic modification in mammalian cells. The present specification describes the design and testing of a polynucleotide encoding the | 05-19-2016 |
| 20160145578 | METHOD FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO MULTI-COMPETENT RENAL PRECURSORS - This application relates to a method for differentiating pluripotent stem cells (PSCs) into multi-competent renal precursor cells expressing Six2. These renal precursor cells are able to differentiate into fully functional and fully differentiated podocytes. Moreover this application relates to a method for differentiating human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) into defined renal precursor cells expressing Six2 and podocytes based on linked steps of chemically defined medium inductions. | 05-26-2016 |
| 20160194623 | NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF | 07-07-2016 |
